公开(公告)号：US20180104322A1

公开(公告)日：2018-04-19

申请号：US15832240

申请日：2017-12-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Ralph Leon BIEMANS ,  Dominique BOUTRIAU ,  Philippe Thomas DENOEL ,  Pierre DUVIVIER ,  Carine GORAJ

IPC: A61K39/085 ,  A61K39/00

CPC classification number: A61K39/085 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70

Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.

公开(公告)号：US20170281744A1

公开(公告)日：2017-10-05

申请号：US15529094

申请日：2015-12-08

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Ralph Leon BIEMANS ,  Dominique BOUTRIAU ,  Philippe DENOEL ,  Pierre DUVIVIER ,  Carine GORAJ

IPC: A61K39/085 ,  A61K45/06 ,  C07K14/31

CPC classification number: A61K39/085 ,  A61K39/00 ,  A61K45/06 ,  A61K2039/555 ,  A61K2039/58 ,  A61K2039/6037 ,  A61K2039/70 ,  C07K14/31 ,  C07K2319/00

Abstract: The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the pH of the composition is pH 5.0-pH 8.0. The application further discloses an immunogenic composition comprising; (i) a S. aureus Type 5 capsular saccharide conjugated to a carrier protein, (ii) a S. aureus Type 8 capsular saccharide conjugated to a carrier protein, (iii) a ClfA protein or immunogenic fragment thereof, (iv) an alpha toxoid, and (v) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0